COHBAR INC (CWBR)       2.19  +0.11 (+5.29%)

2.19  +0.11 (+5.29%)

US19249J3077 - Common Stock - After market: 2.19 0 (0%)


Fundamental Rating

3

Taking everything into account, CWBR scores 3 out of 10 in our fundamental rating. CWBR was compared to 639 industry peers in the Biotechnology industry. The financial health of CWBR is medium. Also its profitability is quite bad. CWBR is valued expensive and it does not seem to be growing.

Note: CWBR has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

1

The Piotroski-F score of CWBR is 4.00. This is a neutral score and indicates average health and profitability for CWBR.

VS Industry

Valuation

Valuation Rating

3

When comparing the current price to the book value of CWBR, it is valued rather cheaply. It is trading at 0.34 times its book value.
Compared to an average industry price book ratio of 1.87, CWBR is valued rather cheaply. On top of this, CWBR is cheaper than 94% of the companies listed in the same industry.

CWBR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CWBR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Price/Book (0.34) VS Industry: 94% outperformed.

464.05
0.07

Growth

Growth Rating

3

CWBR is expected to show a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 20.19% yearly.

CWBR shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.85%.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 7.85% 46.45% 20.19% N/A N/A
RevenueN/A N/A N/A N/A N/A N/A N/A

Health

Health Rating

6

CWBR has a Current Ratio of 34.81. This indicates that CWBR is financially healthy and has no problem in meeting its short term obligations.
The Current Ratio of CWBR is much better than the industry average of 6.21. CWBR has a better rating than 97% of its industry peers.
CWBR has a Quick Ratio of 34.81. This indicates that CWBR is financially healthy and has no problem in meeting its short term obligations.
The Quick Ratio of CWBR is much better than the industry average of 6.11. CWBR has a better rating than 97% of its industry peers.

The Debt to Equity ratio of CWBR is in line with the industry averages.
CWBR has a Altman-Z score comparable to the industry average, which is at -0.13.
The Piotroski-F score of CWBR is 4.00. This is a neutral score and indicates average health and profitability for CWBR.
CWBR has an Altman-Z score of -0.54. This is a bad value and indicates that CWBR is not financially healthy and even has some risk of bankruptcy.
VS Industry

Debt/Equity (0) VS Industry: 42% outperformed.

15.37
0.00

Quick Ratio (34.81) VS Industry: 97% outperformed.

0.04
84.53

Current Ratio (34.81) VS Industry: 97% outperformed.

0.08
85.09

Altman-Z (-0.54) VS Industry: 47% outperformed.

-94.22
622.88

Dividend

Dividend Rating

0

CWBR does not give a dividend.

COHBAR INC2.19

NASDAQ:CWBR (1/27/2023, 7:01:54 PM)+0.11 (+5.29%)

After market: 2.19 0 (0%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-08 2022-11-08/amc Earnings (Next) 03-27 2023-03-27
Inst Owners 0.26% Inst Owner Change -12.25%
Ins Owners 7.17% Ins Owner Change 75.45%
Market Cap 6.37M Analysts 43.33
Price Target 18.36 (738.36%)

Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A

Surprises & Revisions
EPS beat(2) 1 Avg EPS beat(2) 21.18%
Min EPS beat(2) 21.18% Max EPS beat(2) 21.18%
EPS beat(4) 3 Avg EPS beat(4) 20.91%
Min EPS beat(4) 12.85% Max EPS beat(4) 28.7%
Revenue beat(2) N/A Avg Revenue beat(2) N/A
Min Revenue beat(2) N/A Max Revenue beat(2) N/A
Revenue beat(4) N/A Avg Revenue beat(4) N/A
Min Revenue beat(4) N/A Max Revenue beat(4) N/A
PT rev (1m) 0% EPS NQ rev (1m) 0%
EPS NY rev (1m) 0% Revenue NQ rev (1m) N/A
Revenue NY rev (1m) N/A

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB 0.34
EV/EBITDA N/A
EPS(TTM) -7.2 EY N/A
EPS(NY) -4 Fwd EY N/A
FCF(TTM) -3.59 FCFY N/A
OCF(TTM) -3.59 OCFY N/A
SpS N/A BVpS 6.45
TBVpS 6.44 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM N/A
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y N/A GM growth 5Y N/A
F-Score 4 Asset Turnover N/A

Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Profit Quality N/A
Current Ratio 34.81
Quick Ratio 34.81
Altman-Z -0.54
F-Score 4 WACC N/A
ROIC/WACC N/A Cap/Depr(3y) 41.1%
Cap/Depr(5y) 129.66% Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 7.85% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 45.33%
EPS Next Y 46.45% EPS Next 2Y 20.19%
EPS Next 3Y N/A EPS Next 5Y N/A
Revenue growth 1Y N/A Revenue growth 3Y N/A
Revenue growth 5Y N/A Revenue growth Q2Q N/A
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
EBIT growth 1Y 33.77% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year N/A
EBIT Next 3Y N/A EBIT Next 5Y N/A
FCF growth 1Y -8.34% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y -10.17%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA